Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRTC Stock Forecast 2026-2027
$17.14
Current Price
$417.22M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRTC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PRTC Price Momentum
+0.6%
1 Week Change
+3.9%
1 Month Change
+2.1%
1 Year Change
+3.0%
Year-to-Date Change
-14.0%
From 52W High of $19.92
+18.2%
From 52W Low of $14.50
📊 TOP ANALYST CALLS
Did PRTC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PureTech is one of their latest high-conviction picks.
Latest PRTC Stock Price Targets & Analyst Predictions
PRTC has shown a year-to-date change of 3.0% and a 1-year change of 2.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PRTC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRTC Analyst Ratings
1
Buy
0
Hold
0
Sell
PRTC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $17.14
Latest PRTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $45.00 |
| Aug 26, 2022 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 25, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $44.00 |
| Aug 9, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $70.00 |
| Jun 15, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $66.00 |
| Jan 7, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $70.00 |
| Aug 25, 2021 | SVB Leerink | Thomas Smith | Outperform | Maintains | $76.00 |
| Jan 15, 2021 | SVB Leerink | Outperform | Initiates | $N/A |
PureTech Health plc (PRTC) Competitors
The following stocks are similar to PureTech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PRTC
PureTech Health
mkt cap
417.22M
PureTech Health plc (PRTC) Financial Data
PureTech Health plc has a market capitalization of $417.22M with a P/E ratio of 10.2x. The company generates $4.66M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -38.2% quarter-over-quarter, while maintaining an operating margin of -1,801.8% and return on equity of -30.9%.
Valuation Metrics
Market Cap
$417.22M
Enterprise Value
$3.97B
P/E Ratio
10.2x
PEG Ratio
-34.3x
Price/Sales
89.6x
Growth & Margins
Revenue Growth (YoY)
-38.2%
Gross Margin
N/A
Operating Margin
-1,801.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
6.6x
Debt/Equity
66.5x
ROE
-30.9%
ROA
-10.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
PureTech Health plc (PRTC) Business Model
About PureTech Health plc
What They Do
Biotechnology company developing innovative therapies.
Business Model
PureTech Health plc generates revenue by discovering and developing new therapies that address major medical challenges. The company focuses on advanced medicine in immunology, oncology, and neuroscience, targeting previously untapped biological and clinical pathways to create solutions that improve patient outcomes.
Additional Information
As an American Depositary Receipt (ADR), PureTech Health allows US investors to easily invest in its shares, which are primarily traded on the London Stock Exchange. This structure broadens its investor base and enhances its influence in the biotechnology sector, positioning the company as a key player in advancing healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
56
CEO
Mr. Robert Lyne J.D., L.L.B.
Country
United States
IPO Year
2020
Website
www.puretechhealth.comPureTech Health plc (PRTC) Latest News & Analysis
Latest News
Quick Summary
PureTech plans to voluntarily delist its American Depositary Shares from Nasdaq and will focus trading on the London Stock Exchange.
Why It Matters
PureTech's delisting from Nasdaq may affect liquidity and investor access, potentially impacting share value and market perception, while focusing on the London Stock Exchange could shift investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech has announced its annual results for the year ended December 31, 2025. Further details on financial performance and key metrics are expected in the report.
Why It Matters
PureTech's annual results provide insight into its financial performance and growth prospects, affecting stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech Health's Seaport Therapeutics has priced its US IPO at $254.9 million. Following the announcement, PureTech shares rose 9.56% to 139.8p.
Why It Matters
Seaport Therapeutics' successful IPO and significant capital raise boost PureTech Health's valuation and market confidence, driving a 9.56% increase in its share price.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
PureTech Health plc (PRTC) held its Q4 2025 earnings call, discussing financial performance and strategic developments. Further details can be found in the call transcript.
Why It Matters
PureTech Health's Q4 2025 earnings call provides insights into financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Seaport Therapeutics, a PureTech founded entity, has appointed Dr. Sharon Mates, founder and CEO of Intra-Cellular Therapies, to its Board of Directors.
Why It Matters
Dr. Sharon Mates' appointment could enhance Seaport Therapeutics' strategic direction and innovation, potentially increasing its market competitiveness and appeal to investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech announced positive topline data from a Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome and acute myeloid leukemia.
Why It Matters
Positive trial results for LYT-200 indicate potential for effective treatment in serious conditions, boosting investor confidence in PureTech's growth and market value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PRTC Stock
What is PureTech Health plc's (PRTC) stock forecast for 2026?
Analyst forecasts for PureTech Health plc (PRTC) are not currently available. The stock is trading at $17.14.
Is PRTC stock a good investment in 2026?
According to current analyst ratings, PRTC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRTC stock?
Price predictions from Wall Street analysts for PRTC are not currently available. The stock is trading at $17.14.
What is PureTech Health plc's business model?
PureTech Health plc generates revenue by discovering and developing new therapies that address major medical challenges. The company focuses on advanced medicine in immunology, oncology, and neuroscience, targeting previously untapped biological and clinical pathways to create solutions that improve patient outcomes.
What is the highest forecasted price for PRTC PureTech Health plc?
Price targets from Wall Street analysts for PRTC are not currently available. The stock is trading at $17.14.
What is the lowest forecasted price for PRTC PureTech Health plc?
Price targets from Wall Street analysts for PRTC are not currently available. The stock is trading at $17.14.
What is the overall PRTC consensus from analysts for PureTech Health plc?
The overall analyst consensus for PRTC is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are PRTC stock price projections?
Stock price projections, including those for PureTech Health plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:44 AM UTC